HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plasma Macrophage Inhibitory Cytokine-1 as a Complement of Epstein-Barr Virus Related Markers in Identifying Nasopharyngeal Carcinoma.

AbstractBACKGROUND:
We evaluated the diagnostic value of plasma Macrophage inhibitory cytokine-1 (MIC-1) in distinguishing patients with nasopharyngeal carcinoma (NPC) and explored its complementary role with widely used Epstein-Barr virus (EBV) related markers, EBV capsid antigen-specific IgA (VCA-IgA) and EBV copy number.
METHODS:
ELISA was used to analyze the plasma MIC-1 levels in 190 NPC patients, 72 VCA-IgA-positive healthy donors (VP), and 219 normal subjects with negative VCA-IgA (VN). 10 pairs of plasma samples before and after radiotherapy were also included.
RESULTS:
The plasma MIC-1 levels were significantly higher in NPC patients (Median: 678.39 ng/mL) than those in VN and VP (310.29 and 294.59, p < 0.001). Receiver operating characteristic (ROC) curves of the MIC-1 concentrations revealed that the area under the ROC curve (AUC) was 0.790 (95% confidence interval [CI]: 0.748-0.832), with a sensitivity of 63.7%, and a specificity of 85.9% respectively, for distinguishing NPC patients from the healthy donors. Similarly, between NPC and VP, ROC was 0.796 (0.738-0.853) with sensitivity of 63.7%, and specificity of 88.9%. In addition, between NPC and VN, ROC was 0.788(0.744-0.832) with sensitivity of 63.7%, and specificity of 84.9%. Further, we found that MIC-1 could complement VCA-IgA and EBV DNA markers, with a negative rate of 88.9% in VCA-IgA-positive healthy controls, and a positive rate of 59.0% in EBV DNA negative NPC patients, respectively. Also, the MIC-1 plasma concentration dropped significantly after radiotherapy (p = 0.027).
CONCLUSIONS:
MIC-1 can complement VCA-IgA titers and EBV DNA copy number tests in NPC detection, improve identification of EBV DNA-negative NPC patients, and distinguish NPC from VCA -IgA positive healthy controls.
AuthorsShan Xing, Huilan Li, Yingqi Pi, Tao Zeng, Qi Huang, Guoping Ou, Ning Xue
JournalTechnology in cancer research & treatment (Technol Cancer Res Treat) 2020 Jan-Dec Vol. 19 Pg. 1533033820956991 ISSN: 1533-0338 [Electronic] United States
PMID33025864 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • GDF15 protein, human
  • Growth Differentiation Factor 15
  • Immunoglobulin A
Topics
  • Adult
  • Aged
  • Biomarkers
  • Disease Susceptibility
  • Enzyme-Linked Immunosorbent Assay
  • Epstein-Barr Virus Infections (complications, virology)
  • Female
  • Growth Differentiation Factor 15 (blood)
  • Herpesvirus 4, Human
  • Humans
  • Immunoglobulin A (blood, immunology)
  • Male
  • Middle Aged
  • Nasopharyngeal Carcinoma (blood, diagnosis, etiology)
  • Neoplasm Staging
  • Prognosis
  • Viral Load

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: